Dr. Eagleton is the Chief of the Massachusetts General Hospital Division of Vascular and Endovascular surgery. An international expert and thought leader on minimally invasive vascular aortic surgery, he also serves as co-director of both the Fireman Vascular Center and the Thoracic Aorta Center at Massachusetts General. Additionally, he is the Program Committee Chair for the prestigious Society for Vascular Surgery. Dr. Eagleton's specialty and passion is endograft therapy for complex aortic disease. He has an extensive experience in basic, translational, and clinical research programs and has been the principal investigator on a several research trials evaluating innovative endovascular therapies for aortic disease. Dr. Eagleton was formerly the Vascular Surgery Director of the Cleveland Clinic Aorta Center. He received his bachelor's degree and medical degree from the University of Rochester, his general surgical training from the University of Rochester Medical Center, and his training in vascular surgery from the University of Michigan.

Dr. Mark Farber is the Director of the University of North Carolina's (UNC) Aortic Disease Management and Endovascular Clinic. He is also the Program Director of Vascular Surgery Fellowship at UNC School of Medicine. He is an international expert on minimally invasive vascular aortic surgery and has been the Principal Investigator on multiple clinical research trials. Dr. Farber holds a bachelor's degree in Chemical Engineering from Cornell University and an MD from Tulane University School of Medicine.

Peter A. Rasmussen, MD, currently serves as the Chief Clinical Officer for CCAW JV, and is a Professor of Neurosurgery in the Cerebrovascular Center/Department of Neurosurgery at the Cleveland Clinic in Cleveland, Ohio.  He is the former Medical Director of Digital Health at the Cleveland Clinic where he oversaw the Clinic’s overall digital health strategy and implementation of their digital medical platforms.  This included the Clinic’s flagship virtual care service “Express Care Online”, as well as site-to-site services and virtual chronic disease management services.    He maintains a busy clinical practice offering patients either open microsurgery or endovascular, minimally invasive treatment options.  As the former Director of the Cerebrovascular Center at the Cleveland Clinic, he founded the Clinic’s telestroke program which has grown to ~1900 teleconsults/year, and he envisioned and implemented the Clinic’s Mobile Stroke Treatment Unit, one of the first two units in the US.  He is a Past-President of the Society of Neurointerventional Surgery, and enjoys international recognition as a cerebrovascular surgery expert.  He is a graduate of the University of Wisconsin Medical School in Madison, Wisconsin, completed his residency in neurosurgery at the University of Wisconsin in Madison, completed fellowship training in interventional neuroradiology/endovascular neurosurgery at the Cleveland Clinic Foundation, as well as a fellowship in microsurgical treatment of cerebrovascular disease also at the Cleveland Clinic.  A recognized innovator and KOL of both digital medicine and endovascular neurosurgery, he is past Vice Chair of the American Association of Neurological Surgeons/Congress of Neurological Surgeons, Cerebrovascular Section, and has been appointed as a fellow of the American Heart Association (FAHA), the American Association of Neurological Surgeons (FAANS), and a founding fellow of the Society of Neurointerventional Surgery (FSNIS). 

Gustavo S. Oderich is Professor of Surgery and Chair of the Division of Vascular and Endovascular Surgery at the Mayo Clinic. He is the Director of the Aortic Center at the Gonda Vascular Center. His areas of interest include management of aortic aneurysms and dissections with advanced endovascular repair using fenestrated and branched stent-grafts. He serves as global principal investigator of the Cook Zenith Plus and Thoracoabdominal Plus trials, and is a site principle investigator in physician-sponsored and industry-sponsored trials investigating novel stent-graft technologies.

Dr. Parodi is an accomplished vascular surgeon at the UNC hospitals, previously at the Cleveland Clinic Miller Heart and Vascular Institute, with specialization in aortic aneurysms, endovascular surgery, peripheral artery disease, and carotid artery disease. A member of the Peripheral Vascular Surgery Society, Dr. Parodi has published many papers and textbook chapters about vascular surgery in several medical journals, covering topics ranging from medical management of aneurysmal disease to complex and novel endovascular techniques. Dr. Parodi earned his medical degree from the University of Buenos Aires, Argentina. He underwent post-doctoral training as an aortic surgical fellow at Cleveland Clinic. After the conclusion of his fellowship in 2013, he was appointed to the Cleveland Clinic medical staff in the Department of Vascular Surgery, where he continues to pursue innovative research to provide the best possible care in the era of modern endovascular therapies.

Rishi Puri, MD, PhD, FRACP, is a coronary and structural interventional cardiologist practicing at Cleveland Clinic, specializing in these minimally-invasive treatments for diseased heart valves, coronary artery disease, and congenital heart disease. Prior to joining Cleveland Clinic to expand the transcatheter aortic valve replacement (TAVR) program, he trained and practiced at other global centers of excellence for innovative transcatheter structural heart therapies, including Quebec Heart and Lung Institute, Rennes University Hospital in France, and the Zurich University Hospital. An expert clinician and an accomplished researcher, he has treated thousands of patients and published hundreds of peer-reviewed manuscripts spanning topics such as vascular structure and function, atherosclerosis progression-regression, novel anti-atherosclerotic compounds, valvular heart disease, and medical device innovation. In addition to his primary appointment at Cleveland Clinic, Dr. Puri serves as Medical Director for the Atherosclerosis Imaging Core Laboratory at the Cleveland Clinic Coordinating Center for Clinical Research, as Associate Professor at Cleveland Clinic Lerner College of Medicine, and as Adjunct Associate Professor at the Institute for Intelligent Systems Research and Innovation at Deakin University in Victoria, Australia. 

Karl West is Cleveland Clinic's Director of Medical Device Solutions. Mr. West has been innovating at Cleveland Clinic since 2002. He is an expert in device design with a concentration in aortic replacement devices such as multi-branched endovascular prosthesis, and holds several patents on novel graft technologies. He is experienced in managing R&D for vascular replacement devices and directing medical device prototyping. Before starting his career at Cleveland Clinic, Mr. West was employed by Philips Medical Systems acting as the lead engineer on computed tomography R&D projects. Mr. West has extensive experience developing a variety of medical devices including several novel image guidance systems. As inventor of the IOPS technology, he led its development and continues to drive the commercialization process. Mr. West has a Bachelor's degree in Mechanical Engineering from Ohio University and a Master's degree in Physics from John Carroll University. He is also an Adjunct Instructor in the Department of Biomedical Engineering at Cleveland State University.

As CEO of Centerline Biomedical, Mr. Rackliffe brings more than 20 years of healthcare experience and executive management, spanning both medical device and pharmaceuticals industries, across both public and private sectors. He has successfully led start-ups, as well as company divisions with over $2 billion in annual revenue.

As a growth catalyst, he has successfully launched more than 25 global life science products focusing on the needs of the patient and those that surround the patient/care environment. In addition, he has led and closed multiple global business development deals to drive synergies and growth. He believes that nothing is achieved without a strong team culture and takes pride in building teams that are both highly diverse and value inclusion.

Mr. Rackliffe received his MBA with high distinction from Joseph M. Katz Graduate School of Business, University of Pittsburgh and a duel major BS from Marquette University.

Dr. Goel is a former World Bank official and global expert on innovation and competitiveness who brings 40 years of international experience in R&D, technology commercialization, and private sector development to his role of President, CFO and member of the Board of Directors for Centerline Biomedical. He is one of the pioneers of Inclusive Innovation, a concept gaining currency as a means of expanding the benefits of technology to a wider global audience. He has led the design and implementation of numerous complex development projects with budgets of up to $500 million. Dr. Goel is also a senior consultant at World Bank (previously Chief of Financial Management), and founder of Lagom Group, an international advisory firm. He holds MBA with distinction and Ph.D. from Cornell University, and a Masters from NDRI, India.

Dr. Ramesh Mashelkar is the National Research Professor, and President of the Global Research Alliance, a network of publicly funded R&D institutes in Asia, Europe, and the United States with over 60,000 scientists. He is the former Director General of Indian Council of Scientific and Industrial Research, overseeing 38 national R&D labs and 5,000 scientists. He was the Chancellor of the Academy of Scientific and Innovative Research. Dr. Mashelkar is also one of the pioneers of the Inclusive Innovation, a concept getting highly popular in emerging economies. He is on the Boards of several leading Indian corporations and top higher education institutions, and the chairman of multiple life science, biotech, and VC companies. He has received 38 honorary doctorates, including those from the University of Wisconsin and University of London. Dr. Mashelkar received his Master's and PhD from the Institute of Chemical Technology in Mumbai, India.

First appointed to the Cleveland Clinic staff in 2001, Sean Lyden, MD, is the Chairman of the Department of Vascular Surgery at Cleveland Clinic’s Sydell and Arnold Miller Family Heart & Vascular Institute. He also serves as Chief Medical Officer of Excelerate Strategic Health Sourcing, a venture between Cleveland Clinic and Vizient to save health care organizations money with a provider-led, physician-engaged sourcing company. He has clinical interests in abdominal aortic aneurysms, carotid artery disease, and lower-extremity endovascular treatments.

Dr. Lyden is a Professor of Surgery in the Department of Vascular Surgery at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is a Fellow of the American College of Surgeons and has been recognized as a Distinguished Fellow of the Society for Vascular Surgery.  He is also a member of many regional vascular societies including the Peripheral Vascular Surgical Society, the Society for Clinical Vascular Surgery, the International Society for Endovascular Specialists and the Midwestern Vascular Surgical Society.

Mr. Johnson is a nearly 30-year veteran of medical device R&D and product development. Having begun his career designing infusion pumps with start-up Deltec Systems, he eventually led the entire diabetes division, bringing in revenues exceeding $40 million in the first year, and navigated mergers and acquisitions by Smiths Industries and Pharmacia. Mr. Johnson moved on to serve as Vice President of R&D for Data Sciences International, establishing a strategy that resulted in rapid and predictable delivery of new products to the market, notably an implantable ECG monitoring platform. Most recently, Mr. Johnson built and managed R&D teams as Vice President of R&D for SuperDimension (acquired by Covidien in 2012 for $350 million and now owned by Medtronic), commercializing a novel electromagnetic navigation platform to diagnose and treat early-stage lung cancer. Mr. Johnson has extensive leadership and engineering experience in the launch of over 30 medical devices with worldwide distribution and holds numerous patents. Having achieved tremendous success in these launches, he continues to pursue his passion for improving the world through medical innovation. He is involved in multiple medical device startups and strongly connected in the medical device industry. He has a Bachelor's degree in Mechanical Engineering from the University of Minnesota.

Frank Grillo has over 23 years of experience in the medical device industry, including roles as Chief Executive officer of AirXpanders, Inc.,  and Chief Executive Officer of MRI Interventions, Inc. Earlier in his career, Mr. Grillo served as Vice President, Marketing and New Business Development of Intuitive Surgical, Inc., a publicly-traded medical technology company, from 2008 to 2014.  Before joining Intuitive Surgical, Mr. Grillo worked for Kyphon Inc. from 2006 to 2008 as Vice President, Marketing and Business Development. Kyphon was a publicly-traded medical technology company prior to its acquisition by Medtronic, Inc. in November 2007.  Prior to Kyphon, from September 1996 to January 2006, Mr. Grillo held various positions at Boston Scientific Corporation.  Mr. Grillo is currently a consultant and advisor in the medical device industry, and serves on the Board of Directors of Embolx, Inc. and Empirical Spine, Inc., both privately held medical device companies.  Mr. Grillo has a BS in Chemical Engineering from Tufts University, and an MBA from Northwestern University.